Market Indices
Sector Heatmap
OCS — Oculis Holding AG Ordinary shares
NasdaqOculis Holding AG Ordinary shares
- O
- 8.83
- H
- 8.83
- L
- 8.35
- V
- 173.68K
OCS — Latest News & Headlines
20 StoriesOCS: Oculis Holding AG Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
OCS: Oculis Holding AG Latest Stock Price, Analysis, News and Trading Ideas Stocktwits
After Plunging 24% in 4 Weeks, Here's Why the Trend Might Reverse for Oculis Holding AG (OCS) - Yahoo Finance
After Plunging 24% in 4 Weeks, Here's Why the Trend Might Reverse for Oculis Holding AG (OCS) Yahoo Finance
Trial results for a potential dry eye drug are on track for around year-end, Oculis says. - Stock Titan
Trial results for a potential dry eye drug are on track for around year-end, Oculis says. Stock Titan
Citi Sees $11 Billion Optical Networking Boom Driven By Google, Nvidia - Investor's Business Daily
Citi Sees $11 Billion Optical Networking Boom Driven By Google, Nvidia Investor's Business Daily
Companies Like Oculis Holding (NASDAQ:OCS) Are In A Position To Invest In Growth - Simply Wall Street
Companies Like Oculis Holding (NASDAQ:OCS) Are In A Position To Invest In Growth Simply Wall Street
(OCS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
(OCS) Price Dynamics and Execution-Aware Positioning Stock Traders Daily
Oculis Holding AG Stock 12‑Month Price Target Cut to $36.33, Implies 317% Upside - TradingView
Oculis Holding AG Stock 12‑Month Price Target Cut to $36.33, Implies 317% Upside TradingView
Oculis to Present Licaminlimab Precision Medicine Data at AAO 2026 Ahead of Year-End PREDICT-1 Readout - Quiver Quantitative
Oculis to Present Licaminlimab Precision Medicine Data at AAO 2026 Ahead of Year-End PREDICT-1 Readout Quiver Quantitative
Lumentum’s $40 EPS Bet Changes Everything (NASDAQ:LITE) - Seeking Alpha
Lumentum’s $40 EPS Bet Changes Everything (NASDAQ:LITE) Seeking Alpha
A five-year multiple sclerosis campaign aims to accelerate research and improve care; Oculis will focus on vision. - Stock Titan
A five-year multiple sclerosis campaign aims to accelerate research and improve care; Oculis will focus on vision. Stock Titan
Stifel reiterates Buy rating on Oculis stock, $40 target - Investing.com
Stifel reiterates Buy rating on Oculis stock, $40 target Investing.com
An enthusiast has created an adapter for three Noctua RTX 5080 Gaming OCs instead of the stock shroud. - GameGPU
An enthusiast has created an adapter for three Noctua RTX 5080 Gaming OCs instead of the stock shroud. GameGPU
Surrozen Gains Momentum as FDA Submission Opens Path for Lead Therapy - Benzinga
Surrozen Gains Momentum as FDA Submission Opens Path for Lead Therapy Benzinga
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS as Vision Industry Partner - Quiver Quantitative
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS as Vision Industry Partner Quiver Quantitative
Lumentum: The Rally May Not Be Over (NASDAQ:LITE) - Seeking Alpha
Lumentum: The Rally May Not Be Over (NASDAQ:LITE) Seeking Alpha
Eight directors remain at Oculis (OCS) after a board member serving since 2017 resigns. - Stock Titan
Eight directors remain at Oculis (OCS) after a board member serving since 2017 resigns. Stock Titan
Six employees can buy Crescent shares for $13.94 each once their options vest. - Stock Titan
Six employees can buy Crescent shares for $13.94 each once their options vest. Stock Titan
Software that maps the heart’s electrical activity gets FDA clearance - Stock Titan
Software that maps the heart’s electrical activity gets FDA clearance Stock Titan
Oculis Holding AG (OCS) Climbs 2.30% to $9.34 as Shares Press Toward Resistance - Impulse Wave - https://www.dars.gov.et/
Oculis Holding AG (OCS) Climbs 2.30% to $9.34 as Shares Press Toward Resistance - Impulse Wave https://www.dars.gov.et/
TransMedics Offers Attractive Entry Point, With Upside Potential Outweighing Risks (TMDX) - Seeking Alpha
TransMedics Offers Attractive Entry Point, With Upside Potential Outweighing Risks (TMDX) Seeking Alpha